Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, Briganti A, Abdollah F. Sood A, et al. Among authors: briganti a. Eur Urol Oncol. 2024 Feb;7(1):27-43. doi: 10.1016/j.euo.2023.06.002. Epub 2023 Jul 8. Eur Urol Oncol. 2024. PMID: 37423774 Review.
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.
Chun FK, Briganti A, Gallina A, Hutterer GC, Shariat SF, Antebie E, Walz J, Roehrborn CG, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Chun FK, et al. Among authors: briganti a. Eur Urol. 2007 Oct;52(4):1067-74. doi: 10.1016/j.eururo.2007.03.018. Epub 2007 Mar 20. Eur Urol. 2007. PMID: 17383807
Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK. Ahyai SA, et al. Among authors: briganti a. Eur Urol. 2008 Apr;53(4):750-7. doi: 10.1016/j.eururo.2007.10.017. Epub 2007 Oct 17. Eur Urol. 2008. PMID: 17964070
11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms.
Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, Franceschelli A, Sanguedolce F, Bertaccini A, Farsad M, Giovacchini G, Fanti S, Grigioni WF, Fazio F, Montorsi F, Rigatti P, Martorana G. Schiavina R, et al. Among authors: briganti a. Eur Urol. 2008 Aug;54(2):392-401. doi: 10.1016/j.eururo.2008.04.030. Epub 2008 Apr 18. Eur Urol. 2008. PMID: 18456393
Pelvic lymph node dissection in prostate cancer.
Briganti A, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE. Briganti A, et al. Eur Urol. 2009 Jun;55(6):1251-65. doi: 10.1016/j.eururo.2009.03.012. Epub 2009 Mar 10. Eur Urol. 2009. PMID: 19297079 Review.
1,481 results